Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 189

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 189
---
 on 3,929,378 Ordinary Shares issued
and outstanding as of September 29, 2025. The number of Ordinary Shares deemed issued and outstanding after this offering is based on
1,000,000 Ordinary Shares offered hereby but assumes no exercise of the Representative’s over-allotment option.

As of September 29, 2025,
and based on their reported registered office, none of our shareholders were U.S. persons. We have also set forth below information known
to us regarding any significant change in the percentage ownership of our Ordinary Shares by any major shareholders during the past three
years. Except where otherwise indicated, we believe, based on information furnished to us by such owners, that the beneficial owners
of the Ordinary Shares listed below have sole investment and voting power with respect to such shares.

Following the closing of
this offering, all of our shareholders, including the shareholders listed below, will have the same voting rights attached to their Ordinary
Shares, and neither our principal shareholders nor our directors and executive officers will have different or special voting rights
with respect to their Ordinary Shares. See “Description of Share Capital—Voting Rights.” A description of any material
relationship that our principal shareholders have had with us or any of our predecessors or affiliates within the past three years is
included under “Certain Relationships and Related Party Transactions.”

Unless otherwise noted below,
the address of each shareholder, director and executive officer is c/o Regentis Biomaterials Ltd., 60 Medinat Hayehudim Street, Herzliya
4676652, Israel.

|                                                             |     | Ordinary     
 Shares       |           |     | Percentage of      
 Ordinary Shares    
 beneficially owned |      |   |     |          |      |   |
| Name of beneficial owner                                    |     | beneficially 
 owned        |           |     | Before             
 offering           |      |   |     | After    
 offering |      |   |
| 5% or Greater Shareholders                                  |     |              |           |     |                    |      |   |     |          |      |   |
| HaisThera Scientific Fund I, L.P.(1)                        |     |              |   616,607 |     |                    | 15.7 | % |     |          | 12.5 | % |
| Ocorian Fund Management S.à r.l (2)                         |     |              |   296,372 |     |                    |  7.5 | % |